CAMP4 THERAPEUTICS CORPORATION (CAMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CAMP4 THERAPEUTICS CORPORATION (CAMP) has a cash flow conversion efficiency ratio of 0.132x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($6.29 Million) by net assets ($47.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CAMP4 THERAPEUTICS CORPORATION - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how CAMP4 THERAPEUTICS CORPORATION's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CAMP liabilities breakdown for a breakdown of total debt and financial obligations.
CAMP4 THERAPEUTICS CORPORATION Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CAMP4 THERAPEUTICS CORPORATION ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BUUU Group Limited Class A Ordinary Share
NASDAQ:BUUU
|
N/A |
|
Astral Resources NL
AU:AAR
|
-0.014x |
|
Angel Oak Mortgage Inc
NYSE:AOMR
|
0.061x |
|
Creative Sensor Inc
TW:8249
|
0.036x |
|
Thayer Ventures Acquisition Corporation II Class A Ordinary Shares
NASDAQ:TVAI
|
0.000x |
|
Honghua Group Limited
F:4HB
|
0.011x |
|
Monument Mining Limited
V:MMY
|
0.113x |
|
Solvar Ltd
AU:SVR
|
0.099x |
Annual Cash Flow Conversion Efficiency for CAMP4 THERAPEUTICS CORPORATION (1989–2025)
The table below shows the annual cash flow conversion efficiency of CAMP4 THERAPEUTICS CORPORATION from 1989 to 2025. For the full company profile with market capitalisation and key ratios, see how much is CAMP4 THERAPEUTICS CORPORATION worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $47.70 Million | $-29.55 Million | -0.620x | +14.14% |
| 2024-12-31 | $63.14 Million | $-45.56 Million | -0.722x | -302.19% |
| 2023-12-31 | $-123.73 Million | $-44.16 Million | 0.357x | -28.21% |
| 2022-12-31 | $-77.53 Million | $-38.54 Million | 0.497x | +1045.01% |
| 2021-12-31 | $80.18 Million | $-4.22 Million | -0.053x | -118.28% |
| 2020-12-31 | $99.32 Million | $28.59 Million | 0.288x | +243.86% |
| 2019-12-31 | $137.92 Million | $11.54 Million | 0.084x | -63.94% |
| 2018-12-31 | $205.65 Million | $47.74 Million | 0.232x | -30.97% |
| 2017-12-31 | $198.92 Million | $66.89 Million | 0.336x | +113.79% |
| 2016-12-31 | $164.00 Million | $25.80 Million | 0.157x | -37.13% |
| 2015-12-31 | $189.45 Million | $47.40 Million | 0.250x | +32.23% |
| 2014-12-31 | $151.38 Million | $28.64 Million | 0.189x | +10.42% |
| 2013-12-31 | $133.15 Million | $22.82 Million | 0.171x | +21.37% |
| 2012-12-31 | $117.55 Million | $16.60 Million | 0.141x | -71.63% |
| 2011-12-31 | $24.98 Million | $12.43 Million | 0.498x | +922.31% |
| 2010-12-31 | $17.60 Million | $857.00K | 0.049x | -62.19% |
| 2009-12-31 | $19.20 Million | $2.47 Million | 0.129x | -78.29% |
| 2008-12-31 | $23.20 Million | $13.76 Million | 0.593x | +3050.37% |
| 2007-12-31 | $73.42 Million | $-1.48 Million | -0.020x | -118.18% |
| 2006-12-31 | $151.25 Million | $16.72 Million | 0.111x | -13.00% |
| 2005-12-31 | $176.11 Million | $22.38 Million | 0.127x | +60.46% |
| 2004-12-31 | $158.29 Million | $12.54 Million | 0.079x | +1.62% |
| 2003-12-31 | $65.36 Million | $5.09 Million | 0.078x | -16.61% |
| 2002-12-31 | $58.62 Million | $5.48 Million | 0.093x | -71.47% |
| 2001-12-31 | $37.58 Million | $12.31 Million | 0.328x | +32.12% |
| 2000-12-31 | $30.28 Million | $7.51 Million | 0.248x | +2277.78% |
| 1999-12-31 | $28.09 Million | $293.00K | 0.010x | -96.49% |
| 1998-12-31 | $20.20 Million | $6.00 Million | 0.297x | +114.85% |
| 1997-12-31 | $21.70 Million | $3.00 Million | 0.138x | +162.86% |
| 1996-12-31 | $24.10 Million | $-5.30 Million | -0.220x | -148.89% |
| 1995-12-31 | $22.90 Million | $10.30 Million | 0.450x | +97.11% |
| 1994-12-31 | $14.90 Million | $3.40 Million | 0.228x | +1027.96% |
| 1993-12-31 | $12.20 Million | $-300.00K | -0.025x | -107.80% |
| 1992-12-31 | $7.30 Million | $2.30 Million | 0.315x | -22.28% |
| 1991-12-31 | $3.70 Million | $1.50 Million | 0.405x | +170.27% |
| 1990-12-31 | $2.00 Million | $300.00K | 0.150x | +50.00% |
| 1989-12-31 | $2.00 Million | $200.00K | 0.100x | -- |
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics C… Read more